BioRegenx, Inc. (BRGX)

Market Cap	10.39M -66.6%
Revenue (ttm)	1.93M -24.6%
Net Income	-18.93M
EPS	-0.02
Shares Out	961.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,163
Average Volume	39,934
Open	0.0108
Previous Close	0.0121
Day's Range	0.0108 - 0.0108
52-Week Range	0.0074 - 0.0300
Beta	-3.56
RSI	44.95
Earnings Date	Apr 13, 2026

About BioRegenx

BioRegenx, Inc. develops, manufactures, and sells medical test equipment and science-based nutritional products in the United States and internationally. The company offers Endocalyx Pro, a dietary supplement targeting microvascular capillary health and a range of other supplements under the MyBodyRx brand name; GlycoCheck software; and other health and wellness devices, such as pulsed electro-magnetic field devices, as well as StimaWELL and ReLounge, an electronic muscle stimulation therapy device; and markets hydrogen water products. It also ...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: William Resides
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: BRGX

Financial Performance

In 2024, BioRegenx's revenue was $2.34 million, a decrease of -31.40% compared to the previous year's $3.41 million. Losses were -$23.05 million, 540.4% more than in 2023.